

Expression of lncRNA MALAT1 in cervical squamous cell carcinoma and its correlation with radiotherapy dose

Huarong Zhao

the First Affiliated Hospital of Xinjiang Medical University

Ruirui Ren

The First Affiliated Hospital of Xinjiang Medical University

Yang Zhang

the First Affiliated Hospital of Xinjiang Medical University

Longge Suo

the First Affiliated Hospital of Xinjiang Medical University

Rui Chen

the First Affiliated Hospital of Xinjiang Medical University

Chen Chen

Xinjiang Medical University

Jiazaila ZaKai

the fifth Affiliated Hospital of Xinjiang Medical University

Lei Zhang (✉ ffaz125@163.com)

the First Affiliated Hospital of Xinjiang Medical University

Huerxidan Niyazi

the First Affiliated Hospital of Xinjiang Medical University

Research Article

Keywords: MALAT1, Cervical squamous cell carcinoma, Radiotherapy

Posted Date: February 28th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1328896/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Expression of lncRNA MALAT1 in cervical squamous cell carcinoma and its**
2 **correlation with radiotherapy dose**

3 Running title:Expression of lncRNA MALAT1 and its radiotherapy dose

4 Huarong Zhao¹, Ruirui Ren², Yang Zhang¹, Longge Suo¹, Rui Chen¹, Chen Chen³,
5 Jiazaila·ZaKai⁴, Lei Zhang^{1*}, Huerxidan·Niyazi^{1*}

6

7 ¹Department of Oncology, the First Affiliated Hospital of Xinjiang Medical University,
8 Urumqi 830054, Xinjiang, China

9 ²Department of Radiotherapy, the First Affiliated Hospital of Xinjiang Medical
10 University, Urumqi 830054, Xinjiang, China

11 ³School of clinical medicine, Xinjiang Medical University, Urumqi 830054, Xinjiang,
12 China

13 ⁴Department of Critical care medicine, the fifth Affiliated Hospital of Xinjiang Medical
14 University, Urumqi 830054, Xinjiang, China

15

16 *Lei Zhang and Huerxidan · Niyazi are both of corresponding author

17 Lei Zhang:The First Affiliated Hospital of Xinjiang Medical University, No.137
18 Liyushan Road, Urumqi, Xinjiang830054, China phone:0991-4366344 email:
19 ffaz125@163.com

20 Huerxidan · Niyazi:The First Affiliated Hospital of Xinjiang Medical University,
21 No.137 Liyushan Road, Urumqi, Xinjiang830054, China phone:0991-4366344 email:
22 Ailifu_zl@163.com

23

24 Word count:4625words

25 Figure number:5

26 Table number:7

27

28 **Abstract**

29 **Background:** To investigate the relationship between the expression of long-chain non-
30 coding RNA (LncRNA) MALAT1 and radiotherapy effect in cervical cancer tissues.

31 **Methods:** Sixty cervical cancer patients with radiotherapy were selected and their tissue
32 samples were collected. Siha cell lines and C-33A cell lines were used as MALAT1
33 high expression group and low expression group. These two cell lines were treated with
34 6 MV X-ray at 0, 2, 4, 6, 8, 10, and 12Gy, and the cell inhibition rate was detected by
35 MTT assay at 24h, 48h, 72h and 96h after irradiation. Apoptosis rate was tested by flow
36 cytometry and the percentage of autophagic cells was evaluated by the MDC method.
37 Quantitative real-time quantitative polymerase chain reaction (qRT-PCR) was used to
38 detect the expression of MALAT1.

39 **Results:** The expression level of MALAT1 was higher in cancer tissues than in paired
40 normal tissues in patients with cervical cancer ($P < 0.05$). And the expression level of
41 MALAT1 in cell line C-33A was significantly lower than that of cell line Siha. Besides,
42 the cell inhibition rate in the MALAT1 low expression group was significantly higher
43 than that in the high expression group, and the percentage of autophagic cells in
44 MALTA1 low expression group was also higher ($P < 0.05$). The percentage of
45 autophagy cells in MALTA1 low expression group was higher than that in the high
46 expression group ($P < 0.05$).

47 **Conclusion:** MALAT1 plays an important role in cervical cancer and it is also a key
48 point to interfere with the radiosensitivity of cervical squamous carcinoma cells.

49 **Keywords:** MALAT1; Cervical squamous cell carcinoma; Radiotherapy

51 **Background**

52 Cervical cancer is one of the common reproductive system tumors in women. There are
53 about 100,000 new cases of cervical cancer in China every year, accounting for 1/5 of
54 the total number of new cases in the world, and it has shown regional growth and early
55 age in recent years [1]. Xinjiang is one of the high incidence areas of cervical cancer in
56 China, and the incidence rate of cervical cancer among Uyghur women in Xinjiang was
57 reported to be 459-527/100,000, which is significantly higher than the national rate
58 (14.6/100,000) [2]. Although most early-stage cervical cancers can be cured by surgery
59 or radiotherapy, 20%-25% of these cases fail to take the treatment due to recurrence
60 and distant metastases [3]. Therefore, predicting new markers of cervical cancer and
61 elucidating the molecular mechanisms of cervical carcinogenesis and metastasis are key
62 issues to improve the survival rate of cervical cancer patients, while evaluating the
63 efficacy of radiotherapy by tumor radiosensitivity testing before treatment is important
64 to provide a strong basis for selecting rational and effective treatment. Therefore, more
65 studies focus on the molecular markers related to the efficacy of radiotherapy.

66 Long-stranded non-coding RNA (lncRNA) is a new type of transcript discovered in
67 recent years, which generally exceeds 200 nt in length and does not have the function
68 of encoding proteins but can function by regulating physiological processes such as
69 mRNA shearing, degradation and translation [4]. lncRNA is also gradually considered as
70 a tumor-related biomolecule and can be used as a new diagnostic target for tumors. The
71 metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was named after
72 its first discovery in human non-small cell lung cancer and was one of the first lncRNAs
73 identified [5]. Studies have shown that MALAT1 is highly expressed in lung, gallbladder,
74 breast, liver, stomach, bladder and cervical cancers [6-10] and is closely associated with
75 tumor metastasis and recurrence [11]. Previous studies have confirmed that MALAT1 is
76 highly expressed in HPV-positive cervical cancer cells and low expressed in HPV-
77 negative cervical cancer cells [12-16].

78 Therefore, in this experiment, we selected stable and suitable cervical squamous
79 carcinoma cell lines Siha (HPV-positive, HPV type 16) and C-33A (HPV-negative).
80 After radiation treatment, the cell inhibition rate, apoptosis rate and autophagy
81 percentage of cervical squamous carcinoma cells were examined to investigate the
82 effect of MALAT1 expression on the sensitivity of radiotherapy for cervical squamous

83 carcinoma, and to provide a scientific basis for the treatment plan of cervical squamous
84 carcinoma with MALAT1 as the target combined with radiotherapy.

85

86 **Materials and methods**

87 **Patients and tissues**

88 Seventy cervical biopsy tissue specimens of Han and Uyghur patients with cervical
89 cancer attending the First Affiliated Hospital of Xinjiang Medical University from
90 January 2017 to December 2019 were selected. Among them, 10 patients were not
91 included in the study because the tissue specimens were not qualified, the patients did
92 not complete radiotherapy, or lost visits. The patients who did not undergo surgery and
93 did not receive chemotherapy or radiotherapy were recruited. All participants signed an
94 informed consent form. All specimens were rapidly placed in liquid nitrogen after
95 collection and then stored in a -80°C refrigerator for backup.

96 All participants were followed up for 48 months, and those who failed to come to the
97 outpatient clinic for review on time were asked by telephone. Survival time was defined
98 as the interval (number of months) from the date of admission to the date of death or
99 last follow-up. The patients' disease progress and survival status were recorded.

100 **Cervical squamous carcinoma cell line**

101 Cervical squamous carcinoma cell line Siha and C-33A (ATCC Cell Bank, Shanghai)
102 were cultured in MEM medium (Hyclone Co., Ltd., USA) containing 10% fetal bovine
103 serum (FBS) (Hyclone Co., Ltd., USA), 1% penicillin (Hyclone Co., Ltd., USA) and 1%
104 streptomycin (Hyclone Co., Ltd., USA) in an incubator with 5% CO₂ and 95%
105 humidity at 37°C. Cell passages were performed when cell fusion reached 80%-90%.

106 **Treatment**

107 Radiotherapy was performed by three-dimensional conformal irradiation or intensity-
108 modulated irradiation (IMRT) with radiation energy of 6 MV-X lines, pelvic large field
109 radiotherapy DT=45-50Gy/23-25f. The target areas included the upper border at the L4
110 and L5 levels; lower border at the inferior border of the pubic symphysis; both sides
111 outside at 1/3c inside the femoral head, including the total iliac 1/2, internal iliac,
112 external iliac, closed hole, presacral and other lymph node areas. After 3 weeks of total

113 pelvic irradiation, we started to use ¹⁹²Ir high dose rate rear-loader for intravaginal
114 rear-load radiation therapy, with a dose of 600 cGy at each A site, for a total of 5 times,
115 once a week, for a cumulative dose of 3000 cGy. Patients with intracavitary rear-load
116 radiation therapy were not feasible for external radiation therapy on the same day, and
117 patients were required to insist on daily vaginal douching during radiation therapy.
118 Patients were given 1-2 cycles of FP chemotherapy according to the patient's tolerance,
119 specifically: cisplatin (PPD) 75mg/m² in 3 days + fluorouracil (5-FU) 1000mg/m² in
120 24-hour micropump for 4 days, and symptomatic treatment such as protection of gastric
121 mucosa and antiemetic during the treatment period.

122 **Evaluation criteria of efficacy**

123 The recent efficacy was judged according to WHO solid tumor efficacy assessment
124 criteria, complete remission (CR): tumor completely disappeared for 4 weeks; partial
125 remission (PR): tumor shrunk more than 50%; lasted for 4 weeks; no change (SD):
126 tumor shrunk less than 50% or enlarged <25%; deterioration (PD): tumor enlarged >25%
127 or appeared lesions. Pelvic examination and combined CT and ultrasound imaging were
128 evaluated by two associate professors of oncology 4 weeks after the end of treatment.
129 Total effective rate (RR) = CR + PR.

130 **Evaluation of expression level of MALAT1**

131 Total mRNA extraction was performed according to the operating instructions of the
132 Trizol RNA extraction reagent (TaKaRa, Japan). Nanodrop was used to determine the
133 content and concentration of mRNA to ensure the integrity of RNA (OD_{260/280} values
134 of 1.8-2.0 were considered as high purity, and the general concentration of 1000ng/ml
135 was more accurate). Total mRNA was reverse transcribed into cDNA according to
136 TaKaRa reverse transcription kit instructions. Polymerase chain reaction (PCR) was
137 performed using SYBR instant PCR kit (Tiangen, Beijing), according to the kit
138 instructions.

139 After reverse transcription of RNA to generate cDNA, Quantitative real-time
140 quantitative PCR (qRT-PCR) was performed and no spurious peaks appeared in the
141 lysis curve analysis, indicating that the amplification products were single and there
142 was no non-specific amplification. Using GAPDH as the internal control, the CT value
143 was calculated automatically at the end of the reaction, i.e. the number of cycles that
144 the fluorescence signal in each reaction tube had gone through when the fluorescence

145 signal reached the set threshold. The CT values of MALAT1 and GAPDH were
146 obtained from the amplification curves, and their expression amounts were calculated
147 by public display.

148 The MALAT1 and internal reference GAPDH primer sequences were as follows:
149 MALAT1: upstream primer 5'-GAATTGCGTCATTTAAAGCCTAGTT-3',
150 downstream primer 5'-GGTTTCATCCTACCACTCCCAATTAAT-3', GAPDH:
151 upstream primer 5'-TGTTGCCATCAATGACCCCTT-3', downstream primer 5'-
152 CTCCACGACGTACTCAGCG-3'. The CT value of paired normal tissues was used as
153 the standard to calculate the relative expression level of MALAT1, which was
154 expressed by applying $2^{-\Delta\Delta ct}$. qRT-PCR was also performed to verify the relative
155 expression of MALAT1 in two cervical squamous carcinoma cell lines. Cells at the
156 logarithmic growth stage were collected by centrifugation.

157 **Ionizing radiation**

158 The irradiation model of the linear gas pedal for radiation treatment of cell lines is the
159 American Varian-CX linear gas pedal. 6 MV X-ray vertical irradiation, 400 cGy/min
160 dose rate, and 100 cm source skin distance were set. The irradiation field was defined
161 to 10 cm × 10 cm and a 96-well cell culture plate at 15 cm × 15 cm was used.

162 **MTT assay**

163 Two cervical cancer cell lines were inoculated in 96-well plates at a concentration of
164 1×10^6 cells per well, while a blank control group was set up. 6 replicate wells were set
165 up in each well and treated with 0, 2, 4, 6, 8, 10 and 12 Gy of X-ray respectively.
166 Furthermore, the cells in the 96-well plates were incubated in a CO₂ incubator for 24,
167 48, 72 and 96 h before MTT assay. We added 20 μL of 5 g/L MTT reagents (Solebro
168 Co., Ltd., USA) to each well. And the cells were continued to incubate at 37 °C for 4
169 h. And then the culture solution was discarded and 150 μL of DMSO was added to each
170 well. And it was shaken at room temperature for 5 min on a shaker, and finally, the
171 absorbance (OD) value at 490 nm with an enzyme marker was measured to calculate
172 the cell proliferation inhibition rate according to the following formula: cell
173 proliferation inhibition rate = $1 - (\text{OD}_{\text{experimental group}} - \text{OD}_{\text{blank group}}) / (\text{OD}_{\text{control group}} - \text{OD}_{\text{blank group}})$.
174

175 **Apoptosis assay**

176 Two cervical cancer cell lines were digested and counted (cell concentration was 1×10^6),
177 and then inoculated into culture flasks. After being cultured for 24h, the cells were
178 attached to the wall and then irradiated with 8 Gy of X-ray. The culture medium was
179 discarded after 48h of further incubation at 37 °C. The cells were digested, centrifuged,
180 collected, and washed with PBS. According to the instructions of the Annexin V kit
181 (BD Co., Ltd., USA), 1ml $1 \times$ Binding Buffer was added firstly. And then 5 μ L of
182 Annexin V and 5 μ L of 7-AAD were added. The cells were incubated for 15 min at
183 room temperature without light and added 400 μ l of $1 \times$ Binding Buffer to the flow tube.
184 Apoptosis was detected using flow cytometry. Three independent replicate experiments
185 were performed and the apoptosis rate was then calculated based on $(Q2+Q3)/(Q1+Q2+$
186 $Q3+Q4)$.

187 **Cell autophagy assay**

188 Pre-treated was in the same way as Apoptosis assay. After digesting and being
189 centrifuged, 100 μ l of $1 \times$ Wash buffer was added to resuspend the cells according to the
190 instructions of the MDC kit (Solebro Co., Ltd., USA). We aspirated 90 μ l of the cell
191 suspension into a new Ep tube, added 10 μ l of MDC stain, mixed gently and stained
192 them at room temperature for 15~45min. The precipitated cells were centrifuged and
193 collected, and then washed twice with 400 μ l of $1 \times$ Wash buffer. We discarded the
194 supernatant and the cells were resuspended by adding 100 μ l of Collection buffer, added
195 dropwise to a slide and coverslip, and the two cell lines were placed under a confocal
196 microscope for observation. The experiment was repeated three times independently.
197 And the percentage of autophagic cells (blue-purple fluorescent cells) in the original
198 field of view of 100 cells was counted by two laboratory teachers who were familiar
199 with the confocal microscopy technique and had been operating it for 5-10 years.

200 **Statistical analysis**

201 SPSS 23.0 statistical software was used for data analysis. The expression level of
202 MALAT1 in cervical cancer tissues was compared with the baseline data and the
203 characteristics of each clinical case and other count data by X2 test. The correlation
204 between MALAT1 expression level and efficacy was tested by rank sum test. The
205 Kaplan-Meier test was used to compare the survival rates of different expression levels.
206 Cox proportional risk model was used to identify independent risk factors for indicators

207 such as expression level on survival. $\alpha=0.05$ was used as the test level and $P<0.05$ was
208 considered a statistically significant difference.

209 **Results**

210 The actual number of patients who participated in the statistical analysis in this study
211 was 60, with patients ages 40-70 years old and an average of 55 years old. Among them,
212 30 were Han Chinese and 30 were Uyghur.

213 **MALAT1 expression in cervical cancer tissues**

214 The qPCR technique was applied to detect the expression of MALAT1 in 60 cases of
215 Han and Uyghur cervical cancer tissues, and MALAT1 was highly expressed in tumour
216 tissues compared to normal tissues and the difference was statistically significant
217 ($P<0.05$).

218 **The relationship between MALAT1 expression and clinicopathological** 219 **characteristics of patients with cervical cancer**

220 Among the 60 patients with cervical cancer, 36 tumour tissues showed low expression
221 of MALAT1 and 24 tumour tissues showed high expression of MALAT1; while there
222 was no correlation with age, ethnicity, degree of tumour differentiation, tumour stage
223 and SCC index ($P>0.05$), see Table 1.

224 **Relationship between MALAT1 expression and recent outcome of cervical cancer**

225 The results showed that there were 16 cases of CR, 10 cases of PR, 27 cases of SD, and
226 7 cases of PD. 4 cases (16.7%) of CR and 2 cases (8.3%) of PR were found in 24 cases
227 of cervical cancer with high MALAT1 expression. 12 cases (33.3%) of CR and 8 cases
228 (22.2%) of PR were found in 36 cases of cervical cancer with low MALAT1 expression.
229 The efficacy of radiotherapy for cervical cancer with low MALAT1 expression was
230 better than that for high expression, and the difference in efficacy between the two
231 groups was statistically significant ($P<0.05$), and the expression of MALAT1 was
232 negatively correlated with the efficacy of cervical cancer, see Table 2.

233 **Relationship between MALAT1 expression and patient survival**

234 The 1- and 2-year survival rates were 80.0% and 59.2% for high MALAT1 expression
235 and 96.7% and 85.9% for low expression, respectively. The survival rate of cervical

236 cancer patients with low MALAT1 expression was higher than that of patients with
237 high expression, as shown in Table 3 and Figure 1.

238 **Univariate analysis of prognostic relevance:**

239 Age, ethnicity, MALAT1 expression, recent outcome, SCC index classification, lymph
240 node metastasis, tumor stage, and tumor differentiation were used as independent
241 variables, and univariate analysis was performed on the dependent prognostic variables.
242 The results showed that the patients' recent efficacy, lymphatic metastasis and
243 MALAT1 expression were statistically significant, while other indicators were not
244 (Table 4).

245 **Multifactorial analysis of prognostic relevance:**

246 A multifactorial analysis of recent outcome, lymph node metastasis, ethnicity and
247 MALAT1 expression (Table 5) showed that outcome was an independent protective
248 factor for the prognosis of cervical cancer patients at 2-year follow-up (OR=0.452, 95%
249 CI: 0.209-0.979, $p=0.044$). Lymph node metastasis (OR=4.231, 95% CI: 1.085-16.506,
250 $P=0.038$) and expression status (OR=4.742, 95% CI: 1.338-16.805, $P=0.016$) were
251 independent risk factors affecting the prognosis of patients with cervical cancer at 2-
252 year follow-up.

253 **Validation of the relative expression of MALAT1 in cervical squamous carcinoma** 254 **cell lines Siha, C-33A**

255 The relative expression of MALAT1 was significantly lower in the cervical squamous
256 carcinoma cell line C-33A than in Siha cells ($P < 0.05$, Table 6). It shows that MALAT1
257 is highly expressed in the HPV-positive cervical squamous carcinoma cell line Siha and
258 lowly expressed in the HPV-negative cervical squamous carcinoma cell line C-33A.

259 According to the relevant literature and the preliminary experiments of our group, the
260 cell concentration of 1×10^6 can cover 80% of the 96-well plate, and the growth is stable
261 and suitable for experimental research. The cell concentration of 1×10^6 Siha and C-33A
262 cells were treated with 2Gy, 4Gy, 6Gy, 8Gy, 10Gy and 12Gy radiation respectively,
263 and the cell inhibition rate showed an increasing trend at 24h, 48h and 72h after
264 irradiation, and the difference of cell inhibition rate at 72h and 96h after irradiation was
265 not statistically significant (see Figure 2). It is reasonable to assume that the cervical
266 squamous carcinoma cell line Siha, C-33A, undergoes irreversible cell death between

267 48h and 72h after irradiation, so 48h was chosen as the time point for subsequent
268 experimental testing. Siha and C-33A cells were treated with 2 Gy, 4 Gy, 6 Gy, 8 Gy,
269 10 Gy and 12 Gy radiation at a cell concentration of 1×10^6 . 48h after irradiation, there
270 was no significant change in the cell inhibition rate after 2Gy irradiation compared to
271 the control group. Except for the 10 Gy irradiation dose, the cell inhibition rate tended
272 to increase with increasing irradiation dose, among which there was no significant
273 difference between the 6 Gy and 10 Gy irradiation doses ($P > 0.05$), and the difference
274 in cell inhibition rate between the 10 Gy and 12 Gy irradiation doses was significantly
275 higher than that between the remaining adjacent radiation dose groups (see Figure 3),
276 which does not exclude that 12 Gy exceeds the tolerance dose of the cervical squamous
277 carcinoma cell line. In summary, we chose 8 Gy as the irradiation dose for the follow-
278 up experiment.

279 The cell concentration of 1×10^6 cervical squamous carcinoma cell line C-33A was
280 significantly higher than that of cervical squamous carcinoma cell line Siha at 48h after
281 X-ray irradiation at 8Gy, i.e. the cell inhibition rate of MALAT1 low expression group
282 was significantly higher than that of MALAT1 high expression group, the difference
283 was statistically significant ($P < 0.05$), see Table 7.

284 **Flow cytometry detection of apoptosis in two cervical squamous carcinoma cell** 285 **lines, Siha and C-33A cells**

286 Two cervical squamous carcinoma cell lines Siha and C-33A at a cell concentration of
287 1×10^6 were irradiated by X-ray at 8Gy and the apoptosis rates were $(55.99 \pm 0.38)\%$
288 and $(64.70 \pm 0.38)\%$, respectively, after continued incubation at 37°C for 48h. The
289 apoptosis rate was significantly higher in the MALTA1 low expression group (C-33A
290 cells) than in the MALAT1 high expression group (Siha cells, Figure 4).

291 **Autophagy percentage of two cervical squamous carcinoma cell lines Siha and C-** 292 **33A cells by MDC method**

293 Two cervical squamous carcinoma cell lines Siha and C-33A with a cell concentration
294 of 1×10^6 were irradiated by X-ray at 8Gy and the percentage of autophagic cells detected
295 after 48h of incubation was $(9.67 \pm 4.16)\%$ and $(32.67 \pm 6.02)\%$ respectively. The
296 percentage of autophagic cells in the MALTA1 low expression group (C-33A cells)
297 was significantly higher than that in the MALAT1 high expression group (Siha cells)

298 (P < 0.05). Representative images of C-33A cells under ordinary microscope and
299 confocal microscope were shown in Figure 5.

300

301 **Discussion**

302 **Correlation of long-lncRNA MALAT1 expression and different ethnic groups**

303 Cervical cancer is the most common malignant tumor among women worldwide, and
304 Xinjiang is one of the high incidence areas of cervical cancer in China. The incidence
305 rate of cervical cancer among Uyghur women in this region is 3-4 times higher than
306 that of Han women in the same region, and the death rate takes first place among ethnic
307 minorities in China. Most of the cervical cancer patients from ethnic minorities in
308 Xinjiang come from remote farming and herding areas with poor economic and medical
309 environments, and the clinical stage at diagnosis is more advanced and the prognosis is
310 worse. Due to the influence of Xinjiang's ethnic customs, early marriage, premature
311 birth and multiple births of Uyghur women, cervical cancer patients in Xinjiang are
312 characterized by an early age of onset and late stage at diagnosis [17]. Because of these
313 characteristics of cervical cancer patients in Xinjiang, this study conducted statistical
314 analysis by the expression of lncRNA MALAT1 between two different ethnic groups,
315 and the results found that there was no difference between ethnic groups. Because there
316 are no studies on the specificity of different ethnic groups, and the sample size of this
317 study was small, etc., we cannot fully affirm that there is no correlation between the
318 expression of lncRNA and ethnic groups Further studies are needed.

319 **Correlation between age and prognosis of cervical cancer**

320 Cervical cancer is a disease that predominantly affects middle-aged and older women,
321 but still occurs in younger patients in censuses. Most of the current domestic and
322 international studies illustrate that the influence of age factors in the prognosis of
323 cervical cancer is uncertain, with some reporting that both youth and old age are
324 unfavorable prognostic factors, especially in advanced cervical cancer, and some
325 studies showing that younger patients have a better prognosis than older ones [18-20]. Our
326 study showed no difference between MALAT1 expression and age of cervical cancer
327 patients (P>0.05), and it can be considered that the age factor is not significantly related
328 to the prognosis of cervical cancer, and age does not affect the radiotherapy efficacy

329 and prognosis of cervical cancer, which may be related to the small number of cervical
330 cancer samples in the elderly group of different ethnic groups in our data (only 15% of
331 all cases).

332 **Correlation between lymph node metastasis and prognosis of cervical cancer**

333 The prognosis of patients with cervical cancer has been greatly improved by combined
334 radiotherapy and chemotherapy, but the overall survival rate of patients has not been
335 significantly improved, mainly because most patients with cervical cancer have
336 developed micrometastases. How to effectively increase the survival rate and improve
337 the quality of patients' survival is a concern. Therefore, in this study, statistical analysis
338 was also performed on the degree of tumor differentiation, tumor stage and SCC
339 indexes. and the difference in the incidence of lymph node metastasis between the two
340 groups was found to be statistically significant ($P < 0.05$). Therefore, adjustment for
341 lymph node metastasis was again analysed by COX regression and the results showed
342 that lymph node metastasis was an independent prognostic influence on cervical cancer
343 ($p < 0.05$) with a relative risk of $OR = 4.742$ (1.338-16.806).

344 **Correlation between MALAT1 expression and radiotherapy efficacy**

345 LncRNA, as a novel tumor marker, plays an important role in the development of
346 cervical cancer. Therefore, predicting new markers for cervical cancer and elucidating
347 the molecular mechanisms of cervical carcinogenesis and metastasis are key issues to
348 improve the survival rate of cervical cancer patients and are also current hot issues in
349 oncology research. Lu et al ^[21] found that MALAT1 expression was significantly higher
350 in radiation-resistant cancer cases than in radiation-sensitive examples by controlling
351 tissue specimens from 50 cervical cancer patients with 25 healthy individuals in
352 radiation-sensitive cases. However, there are no similar studies about the correlation
353 between MALAT1 and radiotherapy efficacy of cervical cancer at home and abroad.
354 Therefore, in this study, the expression of MALAT1 in the tissues of cervical cancer
355 patients of different ethnic groups was statistically analyzed simultaneously with the
356 radiotherapy efficacy and survival rate. And it was found that the survival rate of
357 cervical cancer patients with low expression of MALAT1 was higher than that of
358 patients with high expression, and the difference was statistically significant ($P < 0.05$).
359 This indicates that there is a correlation between the expression level of MALAT1 and
360 radiotherapy efficacy.

361 **Correlation between MALAT1 expression and other**

362 It was reported that the expression of MALAT1 was associated with HPV. In our
363 current project, HPV-positive cervical squamous carcinoma cell line Siha was in the
364 high MALAT expression group and HPV-negative cervical squamous carcinoma cell
365 line C-33A was in the low MALAT expression group.

366 Radiation prevents tumour cells from cloning due to loss of proliferative capacity, and
367 several studies have used cell proliferation activity as an indicator of sensitivity to
368 radiotherapy [22-23]. In this study, the cell inhibition rate of two cervical cancer cell lines
369 irradiated with 8Gy X-rays for 48h was also measured by MTT. It was confirmed that
370 the cell inhibition rate of MALAT1 low expression group was significantly higher than
371 that of MALAT1 high expression group after irradiation, indicating that MALAT1 low
372 expression could reduce the radiation-induced cell proliferation activity. Radiotherapy
373 can simultaneously activate multiple receptor signalling pathways within tumour cells,
374 altering cell cycle progression and affecting apoptosis [24]. Rugan et al [25] found that
375 the apoptosis of tumor cells did not change significantly after down-regulation of
376 lncRNA MALAT1, however, when combined with irradiation treatment, the apoptosis
377 rate of tumor cells increased significantly. This suggests that MALAT1 is not directly
378 involved in the apoptotic process, but that after radiation-induced apoptosis, lncRNA
379 MALAT1 indirectly regulates the function of Bcl-2/Bax gene, thus indirectly affecting
380 the radiosensitivity of tumor cells through the apoptotic pathway. Meanwhile, our
381 results confirmed that the apoptosis rate in the MALTA1 low expression group (HPV-
382 negative cervical squamous carcinoma cell line C-33A) was significantly increased
383 compared to the MALAT1 high expression group (HPV-positive cervical squamous
384 carcinoma cell line Siha) 48h after irradiation with 8Gy in both cervical squamous
385 carcinoma cell lines, and the difference was statistically significant ($P<0.05$). We
386 suggest that high expression of MALAT1 inhibits apoptosis and interference with
387 MALAT1 expression inhibits the proliferation of cancer cells and promotes their
388 apoptosis, and we speculate that MALAT1 may regulate the sensitivity of radiotherapy
389 for cervical cancer by affecting apoptosis. Furthermore, MALAT1 is an important gene
390 that regulates radiation-induced apoptosis. We found that by promoting radiation-
391 induced apoptosis, we can increase the sensitivity of tumour cells to radiotherapy,
392 improve prognosis, and thus improve patient survival and quality of life. However, due
393 to the variety of signalling pathways involved in apoptosis and the complexity of the

394 relationships, we have only investigated the possible regulatory mechanisms between
395 MALAT1 and apoptosis rates. In-depth studies on the role of MALAT1 in relation to
396 radiation-induced apoptotic factors and their related pathways could provide new
397 approaches to the treatment of tumours. Cell death is divided into programmed and non-
398 programmed death, non-programmed death and cell necrosis, and programmed cell
399 death including apoptosis and cell autophagy. Radiation affects autophagic flow
400 through the fusion of autophagosomes with lysosomes, and several studies have shown
401 that several factors regulate radiation-induced autophagy and thus the sensitivity of
402 tumour cells to radiotherapy^[26-27] . In this study, after irradiation of two cervical
403 squamous carcinoma cell lines with 8Gy, the percentage of autophagic cells was
404 significantly increased in the MALAT1 low expression group (HPV negative cervical
405 squamous carcinoma cell line C-33A) compared to the MALAT1 high expression
406 group (HPV positive cervical squamous carcinoma cell line Siha),, indicating that
407 MALAT1 low expression promotes radiation-induced autophagy in cervical cancer
408 cells. Therefore, by promoting radiation-induced autophagy in tumour cells, the
409 sensitivity of tumour cells to radiotherapy can be increased.

410 However, there are still shortcomings in our study, for example, our study subjects are
411 only cell lines and we have not studied the development process of malignant tumour
412 in human body dynamically, and pure cell experiments cannot meet all aspects of
413 human microenvironment, so we can adjust these shortcomings in the next step and
414 further explore the regulatory mechanism of sensitivity to radiotherapy for cervical
415 cancer, so as to provide effective therapeutic measures for the treatment of cervical
416 cancer as early as possible and make the experiment more rigorous to provide a basis
417 for clinical treatment.

418 **Conclusion**

419 The study showed that MALAT1 plays an important role in regulating the sensitivity
420 of cervical squamous carcinoma cells to radiotherapy, and further investigated its
421 regulatory mechanism. Low MALAT1 expression inhibited tumor cell proliferation,
422 promoted apoptosis and autophagy, suggesting that MALAT1 is involved in regulating
423 the sensitivity of cervical squamous cancer cells to radiotherapy and may be a useful
424 biological marker for predicting radiotherapy efficacy and prognosis.

425 **Authors' contributions**

426 HR-Z, RR-R and YZ designed the study and wrote the first draft of the manuscript and
427 conducted the statistical analysis. LS ,RC and CC performed the data collection and
428 took part in statistical analysis. JZ ,LZ and HN provided critical input into the data
429 analysis and interpretation of the results. HR-Z participated in conception, designed of
430 the study and revised it critically for important intellectual content. All authors have
431 read the draft critically to make contributions and also approved the final manuscript.

432 **Acknowledgments**

433 Not applicable.

434 **Funding**

435 Youth Fund of Natural Science Foundation in Xinjiang Uygur Autonomous Region in
436 2019

437 **Ethical approval**

438 This study was approved by the Research Ethics Committee at the the First Affiliated
439 Hospital of Xinjiang Medical University

440 **Consent for publication**

441 Not applicable

442 **Availability of data and materials**

443 The data is available upon reasonable request

444 **Conflict of Interest Statement**

445 The authors have no conflicts of interest to declare.

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464 **References**

- 465 1. Cai DH., Li Y, Guo RM, et al. Correlation study of HPV typing with Th17 and
466 Treg cells in cervical cancer. *Chinese Clinical Oncology*, 2017, 43 (63): 1099-1102.
- 467 2. Brianti P, DE Flammieis E, Mercuri SR. Review of HPV-related diseases and
468 cancers. *New Microbiol*, 2017, 40 (2):80-85.
- 469 3. Lee J, Lin JB, Sun FJ, et al. Safety and efficacy of semi extended field intensity-
470 modulated radiation therapy and concurrent cisplatin in locally advanced cervical
471 cancer patients: An observational study of 10-year experience. *Medicine*
472 (Baltimore) , 2017, 96(10): e6158.

- 473 doi: 10.1097/MD.00000000000006158
- 474 4. Barker HE, Paget JT, Khan AA, et al. The tumour microenvi-ronment after
475 radiotherapy: mechanisms of resistance and recurrence. *Nat Rev Cancer*, 2015,
476 15(7): 409-425. doi: 10.1038/nrc3958
- 477 5. Powell ME. Modern radiotherapy and cervical cancer. *Int J Gynecol Cancer*, 2010,
478 20(6):49-51.
479 doi: 10.1111/igc.0b013e3181f7b241
- 480 6. Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer.
481 *Gynecol Oncol*, 2010, 116(7):140-146. doi:10.1016/j.ygyno.2009.09.040
- 482 7. Luo YH, Ye L, Kong DL, et al. Correlation between highly expressed lncRNAs
483 and tumorigenesis development and its clinical application value. *Modern medical*
484 *oncology*, 2016, 24(22): 3654-3659.
- 485 8. Zhou XL, Wang WW, Zhu WG, et al. High expression of long non-coding RNA
486 AFAP1-AS1 predicts chemoradio resistance and poor prognosis in patients with
487 esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
488 *Mol Carcinog*, 2016, 55 (12): 2095-2105. doi:10.1002/mc.22454
- 489 9. Jing L, Yuan W, Ruofan D, et al. HOTAIR enhanced aggressive biological
490 behaviors and induced radioresistance via inhibiting p21 in cervical cancer.
491 *Tumour Biol*, 2015, 36(5):36 11-3619. doi: 10.1007/s13277-014-2998-2
- 492 10. Jiao Y, Liu C, Cui F M, et al. Long intergenic non-coding RNA induced by X-ray
493 irradiation regulates DNA damage response signaling in the human bronchial
494 epithelial BEAS-2B cell Line. *Oncol Lett*, 2015, 9(1):169-176.
495 doi: 10.3892/ol.2014.2622

- 496 11. Zhang Mengmei. Changes of serum MALAT1 expression in non-small cell lung
497 cancer patients before and after radiotherapy and its clinical significance. Zunyi
498 Medical College, 2018.1-43.
- 499 12. Rugan. Study on the effect of LncRNA-MALAT1 and Hsa-miR-1 interaction
500 mechanism on radio sensitivity of colorectal cancer. Suzhou:Soochow University,
501 2015.1-66.
- 502 13. Li Z, Zhou Y, Tu B, et al. Long noncoding RNA MALAT1 affects the efficacy of
503 radiotherapy for esophageal squamous cell carcinoma by regulating Cks1
504 expression. *J Oral Pathol Med*, 2016. doi: 10.1111/jop.12538
- 505 14. Liberal V, Martinsson-Ahlzen HS, Liberal J, et al. Cyclindependent kinase subunit
506 (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier
507 triggered by activated oncoproteins. *Proc Natl Acad Sci U S A*, 2012, 109 (8):
508 2754-2759. doi: 10.1073/pnas.1102434108
- 509 15. Jin C, Yan B, Lu Q, et al. The role of MALAT1/miR-1/slug axis on radio resistance
510 in nasopharyngeal carcinoma. *Tumour Biol*. 2016 Mar; 37 (3): 4025-33.
511 doi: 10.1007/s13277-015-4227-z
- 512 16. Liu S, Song L, Zeng S, et al. MALAT1-miR-124-RBG2 axis is involved in growth
513 and invasion of HR-HPV-positive cervical cancer cells. *Tumour Biol*, 2016, 37 (1):
514 633-640. doi: 10.1007/s13277-015-3732-4
- 515 17. Lu H, He Y, Lin L, et al. Long non-coding RNA MALAT1 modulates
516 radiosensitivity of HR-HPV+ cervical cancer via sponging miR-145. *Tumour Biol*,
517 2016, 37 (2):1683-1691. doi: 10.1007/s13277-015-3946-5

- 518 18. Sun R, Qin C, Jiang B, et al. Down-regulation of MALAT1 inhibits cervical cancer
519 cell invasion and metastasis by inhibition of epithelial-mesenchymal transition.
520 Mol Biosyst, 2016, 12 (3):952-962. doi: 10.1039/c5mb00685f
- 521 19. Yang L, Bai HS, Deng Y, et al. High MALAT1 expression predicts a poor
522 prognosis of cervical cancer and promotes cancer cell growth and invasion. Eur
523 Rev Med Pharmacol Sci, 2015, 19(17):3187-3193.
- 524 20. Jiang Y, Li Y, Fang S, et al. The role of MALAT1 correlates with HPV in cervical
525 cancer. Oncol Letters, 2014, 7(6):2135-2141. doi: 10.3892/ol.2014.1996
- 526 21. Zhang JY, Feng LY, Rui JC, et al. Study on the correlation between high-risk HPV
527 infection and cervical cancer and precancerous lesions in Jiangsu women. Modern
528 Biomedical Progress, 2016, 16(36):7135-7139.
- 529 22. Zhang L, Hulsidan N, Dilidhar S, et al. Differential expression of long-stranded
530 non-coding RNA MALAT1 in serum and tissues of cervical cancer. Journal of
531 Xinjiang Medical University, 2018, 41(4):478-485.
- 532 23. Lin S, Meng LN, Shan D, et al. Effect of different targeted drugs on the sensitivity
533 of non-small cell lung cancer cell lines with abnormal EGFR expression . Clinical
534 misdiagnosis and misdiagnosis, 2019, 32(9): 87-94.
- 535 24. Chen JY, Zhang F, Zhuang YX, et al. The effect of serpentine on the proliferation
536 and radiotherapy sensitivity of CNE2 stem cells in hypodifferentiated
537 nasopharyngeal carcinoma. Chinese Traditional and Herbal Drugs, 2018, 49
538 (16):3854-3860.

- 539 25. Jeggo PA, Geuting V, Lobrich M. The role of homologous recombination in
540 radiation-induced double-strand break repair. *Radiother Oncol*, 2011, 101 (1):7-12.
541 doi: 10.1016/j.radonc.2011.06.019
- 542 26. Guo D, Ma J, Yan L, et al. Down-regulation of lncRNA MALAT1 attenuates
543 neuronal cell death through suppressing beclin1-dependent autophagy by
544 regulating miR-30a in cerebral ischemic stroke. *Cell Physiol Biochem*, 2017, 43
545 (1):182-194. doi: 10.1159/000480337
- 546 27. Huang J, Yang Y, Fang F, et al. MALAT1 modulates the autophagy of
547 retinoblastoma cell through miR-124-mediated stx17 regulation. *J Cell Biochem*,
548 2018, 119 (5):3835-3863. doi: 10.1002/jcb.26464

549

550

551

552

553

554 **Figure 1** Relationship between MALAT1 expression and long-term outcome of
555 cervical cancer

556 **Figure 2** Comparison of cell inhibition rates of Siha, C-33A cells with a cell
557 concentration of 1×10^6 after 2Gy, 4Gy, 6Gy, 8Gy, 10Gy, and 12Gy irradiation

558 **Figure 3** Comparison of cell inhibition rates of Siha and C-33A cells with a cell
559 concentration of 1×10^6 after 48 hours of irradiation with 2Gy, 4Gy, 6Gy, 8Gy, 10Gy,
560 and 12Gy

561 **Figure 4** Effect of the expression of MALAT1 on apoptosis of cervical cancer cell lines
562 Siha and C-33A cells

563

564 Note: The detection error in the upper left quadrant Q1 is within the permitted range; the upper right
565 quadrant Q2 (7AAD + / PE-) shows non-viable cells, that is, necrotic cells and late apoptotic cells;
566 the lower left quadrant Q3 (7AAD- / PE +) shows early decay. Dead cells; live cells (7AAD- / PE-)
567 are shown in the lower right quadrant.

568 **Figure 5** Taking C-33A cells as an example, comparing cell staining in two fields of
569 view ($\times 4$)

570

571 Note: A is C-33A cells in the ordinary field of view; B. C-33A cells in the field of the confocal
572 microscope; C is Siha cells in the field of common vision; B is Siha cells in the field of confocal
573 microscope

Figures




Figure 1

Relationship between MALAT1 expression and long-term outcome of cervical cancer




Figure 2

Comparison of cell inhibition rates of Siha, C-33A cells with a cell concentration of 1×10^6 after 2Gy, 4Gy, 6Gy, 8Gy, 10Gy, and 12Gy irradiation






Figure 3

Comparison of cell inhibition rates of Siha and C-33A cells with a cell concentration of 1×10^6 after 48 hours of irradiation with 2Gy, 4Gy, 6Gy, 8Gy, 10Gy, and 12Gy



Siha Cell




C-33A Cell

Figure 4

Effect of the expression of MALAT1 on apoptosis of cervical cancer cell lines Siha and C-33A cells

Note: The detection error in the upper left quadrant Q1 is within the permitted range; the upper right quadrant Q2 (7AAD + / PE-) shows non-viable cells, that is, necrotic cells and late apoptotic cells; the lower left quadrant Q3 (7AAD- / PE +) shows early decay. Dead cells; live cells (7AAD- / PE-) are shown in the lower right quadrant.



A

B

Figure 5

Taking C-33A cells as an example, comparing cell staining in two fields of view ($\times 4$)

Note: A is C-33A cells in the ordinary field of view; B. C-33A cells in the field of the confocal microscope; C is Siha cells in the field of common vision; B is Siha cells in the field of confocal microscope